Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
A prospective, observational study in a university hospital (UZ Leuven). Patients are
included when they are treated with a potentional QT-prolonging drug: haloperidol for
delirium, antibiotics (moxifloxacin, levofloxacin, azithromycin, clarithromycin,
erythromycin, co-trimoxazole), antimycotics (ketoconazole, itraconazole, fluconazole,
voriconazole), methadone, tacrolimus and oral oncolytics.
An ECG is taken before the administration of the drug and 3-5 days after starting the drug to
investigate the change in duration of the QTc-interval. Risk factors for developing
QT-prolongation will be documented. Together with ECG2, an additional blood sample will be
collected to measure the blood concentration of the drug.
Details
Lead Sponsor:
Katholieke Universiteit Leuven KU Leuven
Collaborator:
Agentschap voor Innovatie door Wetenschap en Technologie